scispace - formally typeset
P

Panagis Filippakopoulos

Researcher at Structural Genomics Consortium

Publications -  140
Citations -  15219

Panagis Filippakopoulos is an academic researcher from Structural Genomics Consortium. The author has contributed to research in topics: Bromodomain & Kinase. The author has an hindex of 52, co-authored 136 publications receiving 13021 citations. Previous affiliations of Panagis Filippakopoulos include University of Oxford & Ludwig Institute for Cancer Research.

Papers
More filters
Journal ArticleDOI

Selective inhibition of BET bromodomains.

TL;DR: A cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains is reported, establishing proof-of-concept for targeting protein–protein interactions of epigenetic ‘readers’, and providing a versatile chemical scaffold for the development of chemical probes more broadly throughout the b romodomain family.
Journal ArticleDOI

Histone recognition and large-scale structural analysis of the human bromodomain family.

TL;DR: Bromodomains are protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks, and a structural mechanism for the simultaneous binding and recognition of diverse diacetyl-containing peptides by BRD4 is uncovered.
Journal ArticleDOI

Targeting bromodomains: epigenetic readers of lysine acetylation

TL;DR: Recent progress in the development of bromodomain inhibitors is highlighted, and their potential applications in drug discovery are highlighted.
Journal ArticleDOI

Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome

TL;DR: 22 human PTP crystal structures are presented that enable a comprehensive analysis of the classical PTP family and a “head-to-toe” dimerization model for RPTPγ/ζ is proposed that is distinct from the “inhibitory wedge” model and provides a molecular basis for inhibitory regulation.
Journal ArticleDOI

Bromodomains as therapeutic targets.

TL;DR: It is likely that BRDs will emerge alongside HATs and HDACs as interesting targets for drug development for the large number of diseases that are caused by aberrant acetylation of lysine residues.